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Purpose: Imbalances between osteogenic and adipogenic differentiation leads to 
diseases such as osteoporosis. The aim of our study was to demonstrate the differ-
ences in extracellular signal-regulated kinase (ERK) phosphorylation during both 
adipogenesis and osteogenesis of human bone marrow-derived stem cells (BMSCs). 
Materials and Methods: Using troglitazone, GW9662 and U0126, we investigat-
ed their role in hBMSC differentiation to adipogenic and osteogenic fates. Results: 
ERK1/2 inhibition by U0126 suppressed proliferator-activated receptor (PPAR)γ 
expression and lipid accumulation, while it decreased the mRNA expression of ad-
ipogenic genes (lipoprotein lipase, PPARγ, and adipocyte protein) and osteogenic 
genes (type I collagen and osteopontin). ERK phosphorylation was transient and 
decreased during adipogenesis, whereas it occurred steadily during osteogenesis. 
Troglitazone, a PPARγ agonist, induced adipogenesis by inhibiting ERK phosphor-
ylation even in an osteogenic medium, suggesting that ERK signaling needs to be 
shut off in order to proceed with adipose cell commitment. Cell proliferation was 
greatly increased in osteogenesis but was not changed during adipogenesis, indicat-
ing that ERK might play different roles in cellular proliferation and differentiation 
between the two committed cell types. Conclusion: The duration and magnitude of 
ERK activation might be a crucial factor for the balance between adipogenesis and 
osteogenesis in human bone marrow-derived stem cells.
Key Words:      Adipogenesis, osteogenesis, ERK, PPARγ, human bone marrow-de-   
rived stem cells
INTRODUCTION
Human bone marrow-derived stem cells (BMSCs) have a capacity to multi-differ-
entiate, into osteoblast, adipocyte, chondrocytes, muscle cells, and neuronal cells, 
and allowing for self-renewal.1 However, imbalances between osteogenic and adip-
ogenic differentiation have been reported to be related to aging or diseases. In aging 
patients, or those with osteoporosis, decreased bone density was observed with re-
duced osteoblast numbers, but with increased adipocyte numbers, suggesting that it Ho Sun Jung, et al.
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marrow (5 mL) aspirates were obtained from the posterior 
iliac crest of three healthy volunteers, aged 30-62 years (2 
females and 1 male), after obtaining approval from the In-
stitutional Review Board (IRB). All of the donors were pa-
tients who underwent bone graft surgery, however, not suf-
fering from any particular disease and were healthy otherwise. 
Human BMSCs were isolated by Percoll density gradient 
centrifugation and cultured in DMEM-low glucose medi-
um (Gibco, Carlsbad, CA, USA) as previously described.13 
Five-passaged cells were used in all experiments. Cells 
were cultured in an adipogenic medium [(DMEM-low glu-
cose supplemented with 10% fetal bovine serum (FBS), 0.5 
mM isobutyl-methylxanthin, 1 μM dexamethasone, 200 μM 
indomethacin and 5 μM insulin (Sigma, St. Louis, MO, 
USA)] or osteogenic medium [(DMEM-low glucose supple-
mented with 10% FBS, 100 mM dexamethasone, 10 mM 
β-glycerophosphate, and 50 μg/mL ascorbic acid-2-phos-
phate (Sigma)]. Human BMSCs were also cultured in an 
adipogenic medium with 25 μM troglitazone, an agonist of 
the PPARγ ligand (Sigma). The MEK1/2 inhibitors, U0126 
(Promega, Madison, WI, USA), and GW9662 (Sigma), an 
antagonist of the PPARγ ligand, were used.
Oil red O staining for adipogenesis 
Cells were rinsed with phosphate-buffered saline (PBS), 
fixed in 3.7% formaldehyde for 20 minutes and stained 
with an Oil Red O solution for 1 hour. The stained cells were 
photographed and destained in 100% isopropyl alcohol for 
20 minutes. The optical density (OD) of the solution was 
measured at 500 nm. The assays were performed in tripli-
cate wells and each experiment was repeated three times.
Alizarin red S staining for osteogenesis 
Cells were rinsed with PBS and fixed with a 1 : 1 acetone: 
methanol solution for 30 seconds. They were stained with 
an Alizarin Red solution for 20 minutes. The stained cells 
were photographed and destained in 10% cetylpyridinium 
chloride monohydrate for 30 minutes. The OD of the solu-
tion was measured at 540 nm. The assays were performed 
in triplicate wells and each experiment was repeated at least 
three times.
RT-PCR 
The total RNA was isolated using an RNeasy kit (Qiagen, 
Valencia, CA, USA), and it was reverse-transcribed using 
an Omniscript kit (Qiagen). PCR reagents were purchased 
from Qiagen and the specific oligonucleotide primers used 
is important to balance adipogenesis and osteogenesis in or-
der to maintain bone structure and volume.
Many cytokines control adipogenesis and osteogenesis in 
BMSCs through multiple signaling pathways. Bone mor-
phogenetic protein (BMP) and transforming growth factor 
(TGF)β control the expression of cbfa1/runx2 in osteoblast 
differentiation through the Sma-and Mad-related protein 
(SMAD) pathway,2 whereas TGFβ and parathyroid hor-
mone (PTH) inhibit adipocyte differentiation.3,4 Dexameth-
asone and 1,25-dihydroxyvitamin D3 inhibit adipogenic 
differentiation, but enhance osteogenic differentiation.5,6 It 
is, therefore, likely that the signals transduced from BMP, 
TGFβ, PTH, and other local factors act in concert to regu-
late the differentiation balance between osteoblasts and adi-
pocytes. The mitogen-activated protein kinase (MAPK) 
pathway is one potential signal transduction pathway that 
may regulate the proliferation and differentiation of BM-
SCs. Activation of the MAPK pathway promotes cell dif-
ferentiation in several cell types such as neuronal cells, T-
cells, and muscle cells.7,8 It is possible to control osteogene-
sis and adipogenesis through the activation or inhibition of 
MAPKs such as extracellular signal-regulated kinase (ERK), 
c-Jun N-terminal kinase (JNK), and p38-reactivating kinase 
(p38). It has been reported that the transdifferentiation be-
tween osteoblasts and adipocytes might be regulated by 
ERK.9 A correlation between ERK and adipocyte differen-
tiation has intensively been studied in mouse 3T3-L1 pre-
adipocytes, however, the results appear contradictory. Inhi-
bition of ERK activity decreased the expression of CCAAT/
enhancer-binding protein (C/EBP)α and peroxisome prolif-
erator-activated receptor (PPAR)γ in adipogenesis, while 
drug or effectors that block adipogenesis activated MAPK 
activity.3,10-12 Overall, little is known about the regulatory 
mechanism of ERK in distinguishing between adipogenesis 
and osteogenesis from human adult stem cells. In this study, 
therefore, we aimed to identify the exact role of ERK played 
during the adipogenesis and osteoblastogenesis of BMSCs, 
and demonstrated the differences in ERK phosphorylation 
during adipogenesis and osteogenesis of human BMSCs, 
using agonists or antagonists of PPARγ ligand as well as 
U0126, an inhibitor of MEK1/2. 
MATERIALS AND METHODS
Primary culture of BMSCs and cell differentiation 
Three bone marrows were included in this study. Bone ERK Phosphorylation in Osteogenesis and Adipogenesis
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1 hour. The membranes were probed with the following 
primary antibodies: activated ERK1/2, ERK1/2, C/EBPα, 
C/EBPβ, PPARγ and GAPDH (Santa Cruz, Santa Cruz, 
CA, USA). The immunoblots were visualized using ECL 
Plus detection kit (Amersham Pharmacia). Photographs 
were quantified using a densitometer and density values for 
the PCR products were normalized to GAPDH values to 
yield a semiquantitative assessment (Multigauge, Fujifilm, 
Tokyo, Japan).
Crystal violet staining
Osteogenesis and adipogenesis were induced in 12-well 
plates for 14 days with each induction medium. Cells were 
fixed with cold methanol and acetone (1 : 1) for 3 minutes. 
After washed twice with distilled water, the cells were stained 
with 20% crystal violet (Merck, Darmstadt, Germany) for 
10 minutes. After washing the cells twice with distilled wa-
ter, the stain absorbance was detected at 595 nm after de-
staining with 95% ethanol. 
RESULTS
Effects of the agonist/antagonist of PPARγ and U0126 
on adipogenic or osteogenic differentiation 
Adipogenic BMSCs treated with GW9662, a PPARγ antag-
were; PPARγ (5’-CCAGAAAGCGATTCCTTCAC, 3’- 
CACGTTAGTTTCACCTCGGA), aP2 (5’-GGCCAG-
GAATTTGACGAAGTC, 3’-AGCGTAACTTGAGAT-
GTTGTAAGACA), LPL (5’-GAGATTTCTCTGTATGG 
CACC, 3’-CTCTTTCACGAGTAAACGTC), Type I col-
lagen (5’-TCCGACCTCTCTCCTCTGAA, 3’-GAGTGG 
GGTTATGGAGGGAT), Osteopontin (5’-CCAAGTAAG 
TCCAACGAAA, 3’-GGTGATGTCCTCGTCTGT), GAP 
DH (5’-GAAGGTGAAGGTCGGAGTC, 3’-GAAGATG-
GTGATGGGATTTC). The reaction products were analyzed 
by 1.5% agarose gel electrophoresis. Photographs were 
quantified using a densitometer and density values for the 
PCR products were normalized to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) values to yield a semiquan-
titative assessment (Multigauge, Fujifilm, Tokyo, Japan).
Western blot analysis 
Cell extracts were prepared with 1x passive lysis buffer 
(Promega), which contained a cocktail of protease and 
phosphatase inhibitors (Sigma). Twenty microgram ali-
quots of cell lysates were separated by 10% SDS-PAGE 
under reducing conditions. Separated proteins were trans-
ferred to a PVDF membrane (Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA) at 50 volts for 2 hours in trans-
fer buffer. Membranes were blocked with 5% skimmed 
milk dissolved in 1x TBST buffer at room temperature for 
Fig. 1. Effect of agonists or antagonists of PPARγ and U0126 on adipogenic or osteogenic differentiation. (A) Human BMSCs were cul-
tured in an adipogenic medium with or without troglitazone (25 μM), GW9662 (20 μM), or U0126 (20 μM) for 7 days. The lysates were sub-
jected to western blot analysis. (B) BMSCs were induced adipocyte differentiation in the adipogenic medium (AD) for 14 days, and 
stained by Oil red O or Alizarin red S. (C) BMSCs were differentiated into osteoblasts in an osteogenic medium (OS) for 14 days, and 
stained by Oil red O or Alizarin red S. (D) The degree of adipogenic or osteogenic differentiation was determined as OD units by destain-
ing (*p < 0.05, vs media). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PPARγ, peroxisome proliferator-activated receptor; 
BMSCs, bone marrow-derived stem cells.
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the adipogenic medium alone or with troglitazone was de-
creased within 1 hour, however, the decrease of ERK phos-
phorylation was recovered by 20 μM GW9662. ERK phos-
phorylation showed a second decrease from day 3 post-
induction in all the groups. This suggests that GW9662 
might inhibit adipogenic differentiation by targeting ERK 
phosphorylation, and that a transient decrease of ERK 
phosphorylation was necessary to initiate adipogenesis 
(Fig. 2A). In osteogenesis, ERK phosphorylation was 
steadily expressed in all groups except for those in the 
U0126-supplemented medium (Fig. 2B). However, a de-
crease of ERK phosphorylation was observed in osteogenic 
cells treated with troglitazone from day 3 to day 5 post-in-
duction, suggesting that troglitazone might induce or trans-
differentiate cells into adipocytes by inhibiting ERK phos-
phorylation even in the osteogenic medium. 
Difference in total cell numbers between adipogenesis 
and osteogenesis
As shown in Fig. 2, different patterns of ERK phosphoryla-
tion were observed during adipogenesis and osteogenesis. 
It is highly likely that different ERK phosphorylation might 
be correlated with cell proliferation because ERK regulates 
cell proliferation as well as cell differentiation. To examine 
the above possibility, human BMSCs were seeded in 12-
onist, showed reduced expression of C/EBPα and PPARγ, 
whereas U0126, MEK1/2 inhibitor, inhibited the expression 
of PPARγ only (Fig. 1A).  BMSCs treated with troglitazone, 
a PPARγ agonist, showed high lipid accumulation at day 14, 
whereas cells treated with GW9662 or U0126 showed a sig-
nificant decrease in adipogenic differentiation (Fig. 1B). This 
suggests that ERK might inhibit adipogenic differentiation 
though PPARγ suppression, but not through C/EBPα or C/
EBPβ. Lipid accumulation was still found in cells treated 
with U0126 compared to cells treated with GW9662, be-
cause U0126 did not strongly inhibit adipogenic regulatory 
genes, indicating that ERK signaling is important but not suf-
ficient to regulate adipogenic differentiation. BMSCs treated 
with troglitazone, GW9662, or U0126 in the adipogenic me-
dium were not stained by Alizarin Red S (Fig. 1B and D). 
Unexpectedly, in the osteogenic medium, troglitazone in-
duced high-lipid accumulation, but it had no inhibitory effect 
on osteogenic differentiation (Fig. 1C and D). As seen with 
the Alizarin Red S staining, neither troglitazone nor GW9662 
inhibited osteogenic differentiation, whereas the osteogenic 
differentiation was significantly suppressed by U0126. 
Phosphorylation of ERK in the adipogenesis and 
osteogenesis of BMSCs
In adipogenesis, ERK phosphorylation in cells cultured in 
Fig. 2. ERK phosphorylation during the adipogenesis and osteogenesis of human BMSCs. (A) Human BMSCs were cultured in an adipo-
genic medium (AD) with or without troglitazone, GW9662, or U0126 for 5 days. The lysates were subjected to western blot analysis using 
antibodies specific for ERK1/2 and pERK. (B) Human BMSCs were cultured in an osteogenic medium (OS) with or without troglitazone, 
GW9662, or U0126. The lysates were subjected to western blot analysis using antibodies specific for ERK1/2 and pERK. ERK, extracellular 
signal-regulated kinase; BMSCs, bone marrow-derived stem cells.
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increased in the osteogenic medium containing troglitazone 
(*p < 0.05, vs. control) (Fig. 4B). These results support the 
idea that adipogenic differentiation could be induced even 
in an osteogenic medium with the addition of troglitazone. 
The expression of type I collagen and osteopontin was in-
creased time-dependently during osteogenesis (data not 
shown), but it was inhibited by U0126. Troglitazone and 
GW9662 did not affect the expression of osteogenic-related 
genes (*p < 0.05, vs. control), suggesting that ERK activa-
tion might play a critical role in both osteogenic and adipo-
genic differentiation, and that ERK has diverse effects ac-
cording to its microenvironment. 
 
DISCUSSION
BMSCs differentiate into distinct lineages through specific 
signaling pathways in their microenvironment. Investiga-
tion of the role of ERK has been focused on the maturation 
of 3T3-L1 preadipocytes into adipocytes, but each report 
has showed controversial results.9,14
In our results, U0126 did not affect the expression of C/
EBPα or C/EBPβ, but inhibited the expression of PPARγ, 
indicating that PPARγ is a downstream target of ERK dur-
ing adipogenesis. Other studies found that ERK activity is 
necessary for the expression of C/EBPα and PPARγ in 
3T3-L1 preadipocytes,12 and that PPARγ is activated by 
ERK or interacts with ERK-kinase1/2 (MEKs) in cancer.15 
well plates with equal numbers of cells and cultured in os-
teogenic or adipogenic induction medium for 14 days. The 
total cell numbers were counted after staining with crystal 
violet,14 a dye that binds to DNA (Fig. 3A), and staining-
pattern of crystal violet was found to be not different in oth-
er donors. There was a great increase in the number of os-
teogenic cells, whereas the total number of adipogenic cells 
did not increase compared to the undifferentiated control 
(Fig. 3B). Based on the different patterns of ERK activation 
between osteogenic and adipogenic differentiation, we sug-
gest the possibility that the increased cell proliferation in 
osteogenic differentiation might be regulated by sustained 
ERK phosphorylation. In contrast, decreased ERK phos-
phorylation might be necessary for adipogenic differentia-
tion by inhibiting cell proliferation. Further cell cycle anal-
ysis would help clarify the role of the ERK signaling in 
relation to cell proliferation of two differentiation systems.
Expression of specific marker genes in the adipogenesis 
or osteogenesis of BMSCs
Adipogenic-specific genes, lipoprotein lipase (LPL), 
PPARγ2 and adipocyte protein (aP2), were inhibited during 
adipogenesis in the medium containing GW9662 or 
U0126, while type I collagen and osteopontin, an osteogen-
ic marker genes, were not expressed (Fig. 4A). The inhibit-
ed adipogenesis by U0126 suggests that LPL and aP2, as 
well as PPARγ2, are regulated by the ERK pathway. In os-
teogenesis, the expression of LPL, PPARγ2, and aP2 were 
Fig. 3. Change in total cell numbers during the osteogenesis and adipogenesis of human BMSCs. (A) Cells were incubated in an osteo-
genic (OS) (c and e) or adipogenic (AD) (d and f) medium for 14 days, and stained by Alizarind red S (a and c), Oil red O (b and d), and 
crystal violet (e and f). a and b are control comparing to adipogenesis and osteogenesis. a and b cultured control medium, DMEM-low 
glucose with 10% fetal bovine serum. (B) Crystal violet (CV) stain was quantified by destaining with 95% ethanol, and expressed as OD 
units (*p < 0.05, vs -OS media). BMSCs, bone marrow-derived stem cells.
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and adipogenic differentiation. ERK activation was sus-
tained during osteogenic differentiation, but decreased dur-
ing adipogenic differentiation, indicating that a decrease of 
ERK activation is necessary to proceed with adipocyte mat-
uration. This possibility was also supported by our observa-
tion that adipogenic differentiation could be induced in an 
osteogenic medium containing troglitazone, accompanied 
with a decrease of ERK activation. These findings are con-
sistent with previous studies that reported a decrease of 
ERK phosphorylation during the maturation of 3T3-L1 pre-
adipocytes,12 and that ERK phosphorylation was not affect-
ed until day 5 in the osteogenic medium.9 Earlier studies 
showed that the inhibition of ERK activation blocked both 
adipogenesis and osteogenesis.9,12 
We suggest, therefore, that ERK is necessary for the dif-
ferentiation of human BMSCs into adipocytes and osteo-
blast, however, it seems to play a different role in each dif-
ferentiation process. It is quite possible that cell proliferation 
would also be affected by ERK activation, because ERK 
regulates two antagonistic processes, cell proliferation and 
differentiation, depending upon the situation.20-22 Further-
more, differentiation of cells requires sustained phosphory-
lation of ERK, whereas transient phosphorylation of ERK 
induces cell proliferation.20,23 According to our results, the 
In addition, C/EBPβ is a target of ERK2 but not ERK1 in 
NIH 3T3 fibroblasts,16 indicating that the effect of ERK on 
the expression of adipogenic transcriptional genes might 
vary between cell lines or species.
In human diseases such as osteoporosis, the balance be-
tween adipocyte and osteoblast differentiation is disrupt-
ed.17,18 Therefore, we compared the inhibitory effect of 
U0126 on differentiation into adipocytes or osteoblasts. Both 
adipogenic and osteogenic differentiation were blocked by 
U0126: osteogenic BMSCs treated with U0126 were not dif-
ferentiated into adipocytes, and also did not induce the ex-
pression of adipogenic-specific genes. In contrast, Jaiswal, et 
al. reported that PD98059, an inhibitor of MEK1, blocks os-
teogenic differentiation of human BMSCs and induces adip-
ogenic differentiation in an osteogenic medium. In osteopro-
genitor KS483 cells, PD98059 dose-dependently inhibits 
osteogenesis, but stimulates adipogenesis through estrogenic 
transcriptional activity. However, U0126 inhibites both os-
teogenesis and adipogenesis,19 suggesting that osteogenesis 
and adipogenesis from human BMSCs are independently 
regulated at the downstream of ERK pathways by the modu-
lation of transcriptional factors.
We also observed a different pattern of ERK phosphory-
lation in the early differentiation stage between osteogenic 
Fig. 4. RT-PCR analysis during the adipogenesis (AD) and osteogenesis (OS) of BMSCs. (A) BMSCs were cultured in the adipogenic medi-
um with or without troglitazone, GW9662, or U0126. Equal aliquots of the total RNA were reverse transcribed and amplified with the oligo-
nucleotide primers specific for LPL, aP2, and PPARγ2. (B) Cells were induced with troglitazone compounds in the osteogenic medium for 
7 days. Equal aliquots of total RNA were reverse transcribed and amplified with the oligonucleotide primers specific for LPL, aP2, 
PPARγ2, Type I collagen, and osteopontin. BMSCs, bone marrow-derived stem cells; LPL, lipoprotein lipase; aP2, adipocyte protein; 
PPARγ2, peroxisome proliferator-activated receptorγ2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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mon roles of ERK in the adipogenesis and osteogenesis of 
human BMSCs. At the initial stage of differentiation, the 
duration and magnitude of ERK activation are highly criti-
cal factors in the determination of osteogenesis and adipo-
genesis of the human BMSCs (Fig. 5). A precise under-
standing of these mechanisms in human BMSCs would 
certainly be crucial to developing potent drugs against dis-
eases modulating the ERK pathway. 
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